Byrne Lee

Byrne Lee

Auto-generated profile, based on publicly available information

Byrne Lee

Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
OEOliver S. Eng
Oliver S. Eng
SDSinziana Dumitra
Sinziana Dumitra
MOMichael O’lEary
Michael O’lEary
MRMustafa Raoof
Mustafa Raoof
MWMark Wakabayashi
Mark Wakabayashi
BLByrne Lee
Byrne Lee
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.1,2 Even at high-volume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems.3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment.3,4

10 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEliza W Beal
Eliza W Beal
LSLorena P. Suarez-Kelly
Lorena P. Suarez-Kelly
CKCharles W. Kimbrough
Charles W. Kimbrough
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston
JGJonathan Greer
Jonathan Greer
JCJordan Cloyd
Jordan Cloyd
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.

1 August 2018 in Surgical Infections
Verified
Journal Article
Closed access
OEOliver S. Eng
Oliver S. Eng
MRMustafa Raoof
Mustafa Raoof
MOMichael P. O'LEary
Michael P. O'LEary
MLMichael W. Lew
Michael W. Lew
MWMark T. Wakabayashi
Mark T. Wakabayashi
BLByrne Lee
Byrne Lee
Background: Maintenance of peri-operative normothermia remains a global quality metric for hospitals. Hypothermia is associated with surgical site infections (SSIs) in colorectal surgery. Patients undergoing cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) can experience multiple complications post-operatively. We sought to investigate the association of peri-operative hypothermia with SSIs in patients undergoing CRS/HIPEC at our institution. Patients and Methods: Patients undergoing CRS/HIPEC from 2009–2017 were identified retrospectively from a prospectively collected institutional database. Hypothermia defined as less than 36.0°C in accordance with the Agency for Healthcare Research and Quality metric. Regression analyses were performed with SSIs diagnosed within 30 days post-operatively as the primary outcome. Results: A total of 170 patients were identified, 14 (8.2%) of whom developed an SSI. Patients who developed an SSI experienced lower median temperatures (p = 0.027) and a greater percentage of operative time in hypothermia (p = 0.008). On a multivariable analysis adjusting for known risk factors for SSI, the percentage of operative time in hypothermia (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.01–1.07, p = 0.008) was the only parameter associated with SSI within 30 days post-operatively. Conclusion: Hypothermia is associated with the development of SSIs in patients undergoing CRS/HIPEC. Our findings suggest that minimizing peri-operative temperatures to less than 36.0°C may decrease peri-operative SSI in this patient population.

14 August 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
IKIoannis T. Konstantinidis
Ioannis T. Konstantinidis
WCWilliam Chu
William Chu
FTFederico Tozzi
Federico Tozzi
CLClayton Lau
Clayton Lau
MWMark Wakabayashi
Mark Wakabayashi
BLByrne Lee
Byrne Lee

6 September 2019 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
Ioannis KonstantinidisIoannis Konstantinidis
Ioannis Konstantinidis
MRMustafa Raoof
Mustafa Raoof
VZVasilena Zheleva
Vasilena Zheleva
KLKelly Lafaro
Kelly Lafaro
CLClayton Lau
Clayton Lau
BLByrne Lee
Byrne Lee

30 May 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OEOliver S. Eng
Oliver S. Eng
SDSinziana Dumitra
Sinziana Dumitra
MOMichael O’lEary
Michael O’lEary
MWMark Wakabayashi
Mark Wakabayashi
TDThanh Dellinger
Thanh Dellinger
BLByrne Lee
Byrne Lee